June 8, 2020

Intravacc and Versatope Sign Research Service Agreement to Develop Universal Influenza Vaccine Based on OMV technology

Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial  vaccines and Versatope, a U.S. biotechnology company developing vaccines and therapeutics, today announced that they have signed a research service agreement to further develop a universal vaccine against influenza based on Intravacc’s innovative Outer Membrane Vesicles (OMV) technology. Both parties will collaborate to further advance the candidate vaccine through clinical development.

In September 2019, Versatope was one of 10 early-stage life sciences companies in Massachusetts to receive funding through the MLSC’s Milestone Achievement Program (MAP), which addresses the needs of early-stage life sciences companies by providing grant funding to execute critical, value-creating technical milestones. MLSC funding will support Versatope’s effort to create a traceable microbial cell line for master cell banking and establish a reproducible and consistent manufacturing process. These activities are critical to the manufacturing and quality control process for an influenza vaccine product.